×
About 2,673 results

ALLMedicine™ Pneumonectomy Center

Research & Reviews  983 results

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT02959463

May 18th, 2022 - PRIMARY OBJECTIVES: I. To determine the safety and tolerability of pembrolizumab administered after radiation therapy in patients with malignant pleural mesothelioma (MPM) who have not undergone extrapleural pneumonectomy. SECONDARY OBJECTIVES: I....

An ACTH-secreting tumor hidden in a congenitally hypoplastic left lung.
https://doi.org/10.1093/icvts/ivac130
Interactive Cardiovascular and Thoracic Surgery; Chen X, Zhang Y et. al.

May 17th, 2022 - Ectopic ACTH syndrome(EAS) has historically been a therapeutic challenge because of difficulty localizing occult ACTH-secreting tumors. Here we report a case of a 67-year-old woman with EAS and had an ACTH-secreting tumour hidden within a congenit...

A Retrospective Study of Effectiveness of Thoracoscopic Lobectomy and Segmentectomy in ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072017
Disease Markers; Xu J, Huang L et. al.

May 10th, 2022 - Surgical treatment is the first choice for non-small-cell lung cancer. To date, there are only few studies on the changes in laboratory indexes in two types of surgery, namely, thoracoscopic lobectomy and segmental pneumonectomy. To investigate th...

Are Sleeves the New-pneumonectomy?
https://doi.org/10.1016/j.athoracsur.2022.03.079
The Annals of Thoracic Surgery; Brandt WS, Kozower BD

Apr 20th, 2022 - Are Sleeves the New-pneumonectomy?|2022|Brandt WS,Kozower BD,|

see more →

Guidelines  1 results

ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lu...
https://doi.org/10.1097/COC.0000000000000154
American Journal of Clinical Oncology; Willers H, Stinchcombe TE et. al.

Mar 25th, 2015 - The integration of chemotherapy, radiation therapy (RT), and surgery in the management of patients with stage IIIA (N2) non-small-cell lung carcinoma is challenging. The American College of Radiology (ACR) Appropriateness Criteria Lung Cancer Pane...

see more →

Clinicaltrials.gov  31 results

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT02959463

May 18th, 2022 - PRIMARY OBJECTIVES: I. To determine the safety and tolerability of pembrolizumab administered after radiation therapy in patients with malignant pleural mesothelioma (MPM) who have not undergone extrapleural pneumonectomy. SECONDARY OBJECTIVES: I....

Exercise Capacity, Pulmonary Function and Physical Activity Level in Patients Lung Cancer Undergoing Pneumonectomy
https://clinicaltrials.gov/ct2/show/NCT04807153

Mar 22nd, 2022 - Pneumonectomy is a high risk surgical procedure compared to lobectomy, segmentectomy and non-anatomical resection. Pneumonectomy causes impairment of respiratory functions and exercise intolerance. Assessment of exercise capacity in pneumonectomy ...

Comparison of LigaSure to Conventional Electrocoagulation in Video-assisted Thoracoscopic Surgery Lobectomy
https://clinicaltrials.gov/ct2/show/NCT03125798

Nov 8th, 2021 - Summary Surgical treatment of lung cancer consists of two elements: anatomical lung resection (segmentectomy, lobectomy or pneumonectomy) followed by mediastinal lymph node sampling (MLNS) or mediastinal lymph node dissection (MLND). Since over la...

Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03523468

Oct 19th, 2021 - In surgical treatment decisions, locally advanced central lung cancer is the most difficult. Locally advanced central lung cancer refers to tumors that have recidivised adjacent organs and tissues, such as the esophagus, tracheal carina, pericardi...

Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT01644994

Sep 29th, 2021 - The aim is to introduce a new therapeutic method of intracavitary chemotherapy (cisplatin) combined with a fibrin carrier (Vivostat®) after pleurectomy/decortication or extrapleural pneumonectomy in a phase I and II study for Malignant Pleural Mes...

see more →

News  54 results

MSK Continues on Groundbreaking Path in Treatment of Mesothelioma
https://www.onclive.com/view/msk-continues-on-groundbreaking-path-in-treatment-of-mesothelioma

Oct 6th, 2021 - Prasad S. Adusumilli, MD Deputy Chief, Thoracic Service Memorial Sloan Kettering Cancer Center Although malignant pleural mesothelioma (MPM) remains a rare disease, Memorial Sloan Kettering Cancer Center has considerable experience with th...

Adjuvant Atezolizumab Shows Improvement in DFS, Time to Relapse in PD-L1+ Stage II-IIIA NSCLC Subgroups
https://www.onclive.com/view/adjuvant-atezolizumab-shows-improvement-in-dfs-time-to-relapse-in-pd-l1-stage-ii-iiia-nsclc-subgroups

Sep 20th, 2021 - Adjuvant treatment with atezolizumab (Tecentriq) led to an improvement in disease-free survival (DFS) and time to locoregional and distant relapse compared with best supportive care (BSC) in prespecified subgroups of PD-L1–positive patients with s...

Novel Neoadjuvant Triplet Shows Preliminary Promise in Resectable Pleural Mesothelioma
https://www.onclive.com/view/novel-neoadjuvant-triplet-shows-preliminary-promise-in-resectable-pleural-mesothelioma

Sep 13th, 2021 - Neoadjuvant treatment with cisplatin/pemetrexed plus atezolizumab (Tecentriq), followed by maintenance atezolizumab, demonstrated early efficacy with acceptable safety in patients with resectable pleural mesothelioma, according to data from an upd...

Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC?
https://www.medscape.com/viewarticle/958588

Sep 11th, 2021 - New data on the use of immunotherapy in early stages of non–small cell lung cancer (NSCLC) have sparked a debate on which patients benefit most. Previous results have already shown that patients with early-stage NSCLC who receive atezolizumab (Tec...

Dr. Spicer on Outcomes from the CheckMate-816 Trial in NSCLC
https://www.onclive.com/view/dr-spicer-on-outcomes-from-the-checkmate-816-trial-in-nsclc

Aug 20th, 2021 - Jonathan Spicer, MD, PhD, assistant professor of surgery, Dr. Ray Chiu Distinguished Scientist in Surgical Research; program director, Advanced Thoracic and Upper GI Surgical Oncology Fellowship; site lead, Rossy Cancer Network Lung Cancer Disease...

see more →